Longeveron updates HLHS trial results and reviews endpoints

Longeveron says treated HLHS trial patients had zero deaths versus one in control, prompting review of exploratory endpoints and FDA discussions. The company also hired an investment bank, cuts costs, and analyzes ELPIS II data.